Thermo Fisher Scientific Inc. (TMO) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q3 2025 earnings beat with raised full-year guidance, strategic AI collaborations, share repurchase program, and positive technical momentum with 7.4% price gain support Thermo Fisher Scientific as an actionable hot idea for moderate near-term growth.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin resilience ⢠Leverage rising ⢠Intangible heavy Thermo Fisher remains a highly profitable cash generator with stable margins and strong free cash flow, but rising leverage, weaker liquidity, heavy intangible assets, and a rich valuation temper upside.
Price Behavior
Key Price Behavior Insights: ⢠Pullback pressure ⢠Key support hold ⢠Reclaim resistance Support Level: $469-$470 Resistance Level: $487-$494 TMO is still modestly higher over the last month, but the post-peak pullback has weakened momentum, making $469-$470 the key near-term support and $487-$494 the rebound trigger.
Sentiment & News
Key News Insights: ⢠Investor Day ⢠Orbitrap Expansion ⢠Dividend Support Thermo Fisher's latest news reinforced its leadership in life sciences through investor-day growth messaging, new Orbitrap and lab expansions, steady dividend returns, and continued analyst support.
AI Summary
Thermo Fisher is still a high-quality compounder, but the investment case now hinges on proving that modest mid-single-digit organic growth can accelerate enough to justify its rich valuation amid Clario integration and higher leverage, making executionânot business qualityâthe key near-term catalyst.
Description
Thermo Fisher Scientific is a global provider of instruments, reagents, consumables and services for life sciences research, clinical diagnostics, and biopharmaceutical production across North America, Europe, Asia-Pacific and other markets. The company operates through four reporting segmentsâlife sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma servicesâselling to pharmaceutical, biotechnology, clinical, academic, government and industrial customers via direct sales, e-commerce and distributors. Founded in 1956, Thermo Fisher is headquartered in Waltham, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 17 | Nov 24 | TMO | Thermo Fisher Scientific Inc. | Q3 2025 earnings beat with raised full-year guidance, strategic AI collaborations, share repurchase program, and positive technical momentum with 7.4% price gain support Thermo Fisher Scientific as an actionable hot idea for moderate near-term growth. | Closed | +3.3% |